Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

NCT07205822 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07205822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07205822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
October 30, 2025
Completion date
February 2, 2028
Enrollment
100 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer